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Abstract P2X3 andP2X2+3 receptors are present on sensory
neurons, where they contribute not only to transient noci-
ceptive responses, but also to hypersensitivity underlying
pathological pain states elicited by nerve injuries. Increased
signalling through P2X3 and P2X2+3 receptors may arise
from an increased routing to the plasma membrane and/or
gain of function of pre-existing receptors. An obvious
effector mechanism for functional modulation is protein
kinase C (PKC)-mediated phosphorylation, since all P2X
family members share a conserved consensus sequence for
PKC, TXR/K, within the intracellularly located N-terminal
domain. Contradictory reports have been published regarding
the exact role of this motif. In the present study, we confirm
that site-directed elimination of the potential phosphor-
acceptor threonine or the basic residue in the P+2 position
of the TXR/K sequence accelerates desensitization of P2X2
receptors and abolishes P2X3 receptor function. Moreover,
the PKC activator phorbol 12-myristate 13-acetate increased
P2X3 (but not P2X2) receptor-mediated currents. Biochem-
ically, however, we were unable to demonstrate by various
experimental approaches a direct phosphorylation of wild-
type P2X2 and P2X3 receptors expressed in both Xenopus
laevis oocytes and HEK293 cells. In conclusion, our data
support the view that the TXR/K motif plays an important
role inP2Xfunction andthatphorbol12-myristate13-acetate
is capable of modulating some P2X receptor subtypes. The
underlying mechanism, however, is unlikelyto involvedirect
PKC-mediated P2X receptor phosphorylation.
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Abbreviations
ATP adenosine 5′-triphosphate
αβ-meATP α,β-methylene adenosine 5′-triphosphate
DMEM Dulbecco’s modified Eagle’s medium
DMSO dimethyl sulfoxide
EGFP enhanced green fluorescent protein
HEK293 human embryonic kidney cell line
mGluR1α metabotropic glutamate receptor subtype 1α
PBS phosphate-buffered saline
PBST 0.1% Tween 20 in phosphate-buffered saline
PKC protein kinase C
PMA phorbol 12-myristate 13-acetate
PMSF phenylmethylsulfonyl fluoride
PVDF polyvinylidene fluoride
SF3B1 splicing factor 3b subunit 1
Introduction
P2X receptors constitute an abundant class of ligand-gated
ion channels, which respond to extracellular ATP and
related nucleotides with the opening of an intrinsic pore
permeable to Na
+,K
+ and Ca
2+ [1, 2]. A family encom-
passing seven P2X subunit genes, designated P2X1–7, has
been identified in rodents and mammals. Six of the seven
subunit isoforms (P2X1-P2X5 and P2X7) are able to
assemble into homotrimeric receptor channels [3–8] with
distinct pharmacological and electrophysiological pheno-
types [9]. According to their sensitivity to the synthetic
ATP analogue α,β-methylene adenosine 5′-triphosphate
(αβ-meATP) and the rate of current desensitization, P2X
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categories: (1) rapidly desensitizing and αβ-meATP sensi-
tive (P2X1 and P2X3) and (2) slowly or non-desensitizing
and αβ-meATP insensitive (P2X2,P 2 X 4 and P2X7)
receptors. The term “non-desensitizing” means that the
currents are maintained for at least a few seconds in the
continuous presence of agonist. A peculiar phenotype is
inherent to heteromeric P2X2/P2X3 (P2X2+3) receptors,
which feature αβ-meATP sensitivity combined with a non-
desensitizing current response.
P2X receptors are found on the surface of a large variety
of cells, where they are involved in numerous sensory pro-
cesses including nociception under both physiological and
pathological processes [10–15]. On nociceptive sensory
neurons, extracellular ATP acts as a pain-producing neuro-
transmitter predominantly through homotrimeric P2X3
receptors or heterotrimeric P2X2+3 receptors. Conditions
and mediators that facilitate P2X3 and P2X2+3 receptor-
mediated signalling, apparently by potentiating ionic cur-
rents, include (1) substance P and bradykinin [16], (2) nerve
injury [17] and (3) calcitonin gene-related peptide (CGRP),
a potent vasodilator and proinflammatory agent [18]. How
this increase in receptor function occurs has not been fully
solved. One obvious candidate mechanism is protein kinase
C (PKC)-mediated phosphorylation, since all P2X family
members share a conserved consensus sequence for PKC-
mediated phosphorylation (TXR/K) within the intracellular-
ly located N-terminal domain (Fig. 1a, b). Indeed, results
obtained with pharmacological activators and inhibitors are
consistent with PKC being involved in P2X3 receptor
potentiation by substance P and bradykinin [16], as well as
the calcitonin gene-related peptide [18]. Direct PKC-medi-
ated phosphorylation has so far been demonstrated only for
the P2X2 receptor, with
18T of the
18TPK
20 sequence as the
phospho-acceptor site [19]. Mutational analysis has further
shown that the TXR/K sequence of the P2X1, P2X2 and
P2X3 receptors plays an important role in controlling the
rate of receptor desensitization [16, 19, 20]. Changes of the
rate of desensitization could profoundly influence the effi-
ciency of synaptic transmission and thus contribute to
pathological pain states. Overall, there is significant interest
in a better understanding of the mechanisms involved in the
short-term and long-term regulation of P2X receptors.
The aim of this study was to assess biochemically the
conditions in which P2X2 and P2X3 receptors become
directly phosphorylated by PKC in a heterologous system.
While this work was in progress, a similar study was
published for the P2X3 receptor that arrived at essentially
the same conclusion, namely that the P2X3 receptor is
unlikely to be a direct PKC substrate [21]. Our results
complement and extend this finding by demonstrating that
the P2X2 receptor also does not serve as a substrate for
direct PKC-mediated phosphorylation.
Materials and methods
Materials
The sources of antibodies, enzymes or peptide substrates are
specified at the appropriate places in the text. Chemicals not
otherwise specified were purchased in the highest available
quality from Sigma-Aldrich (Taufkirchen, Germany) or
Merck (Darmstadt, Germany).
Peptide-specific antibodies to P2X1,P 2 X 2
and P2X3 subunits
Peptides ATSSTLGLQENMRTS (residues 385-399 of the
P2X1 subunit), QQDSTSTDPKGLAQL (residues 458–472
of the P2X2 subunit) and VEKQSTDSGAYSIGH (residues
383–397 of the P2X3 subunit) were selected based on their
lack of similarity with known proteins and predicted
hydrophilicity for raising polyclonal antibodies against the
C-terminal end of the rat subunits P2X1,P 2 X 2 and P2X3,
respectively. Rabbit polyclonal antibodies were ordered
through the Custom Antibody Production Services of
Eurogentec (Seraing, Belgium). After 3 months and a total
of four immunizations, rabbits were sacrificed by complete
bleeding. Peptide-specific antibodies were purified from the
serum by affinity columns coupled with the peptides used
for immunization. Immunoblotting showed that the anti-
bodies recognized only the receptor against which they
were raised, thus demonstrating isoform specificity of these
antibodies (results not shown). The antibodies were
aliquoted at 0.12–0.16 mg/ml in phosphate-buffered saline
(PBS) containing 0.1% bovine serum albumin (BSA) and
0.01% thimerosal and stored at −80°C.
cDNA constructs
Plasmids encoding wild-type and N-terminal hexahistidine-
tagged (His-tagged) versions of rat P2X1 subunits (rP2X1,
GenBank accession no. X80477), P2X2 subunits (rP2X2,
GenBank accession no. U14414) or rat P2X3 subunits
(rP2X3, GenBank accession no. X90651) in the oocyte
expression vector pNKS2 [22] were available from previ-
ous studies [3, 8]. Insertion and replacement mutations
were introduced by QuikChange site-directed mutagenesis
(Stratagene, La Jolla, CA, USA). For protein expression in
mammalian cells, the receptor cDNAs were subcloned from
the oocyte expression vector pNKS2 into pcDNA3.1. The
plasmid His-rP2X2-EGFP-pcDNA3.1 with a C-terminal
enhanced green fluorescent protein (EGFP) fusion was
generated by eliminating the stop codon in His-rP2X2 and
adding the coding sequence of EGFP (Clontech, Palo Alto,
CA, USA) in frame. All constructs were verified by
restriction analysis and nucleotide sequencing. A pEGFP-
378 Purinergic Signalling (2007) 3:377–388C1 plasmid harbouring the N-terminally EGFP-tagged
splicing factor SF3B1 was kindly provided by our
colleague Dr. Walter Becker [23].
P2X receptor expression in Xenopus laevis oocytes
Capped cRNAs were synthesized from plasmids linearized
downstream to the 100 bp long polyA tail provided by the
oocyte expression vector pNKS2 [22] and injected at
0.5 μg/μl in 50-nl aliquots into collagenase-defolliculated
X. laevis oocytes using a Nanoliter 2000 injector (WPI,
Sarasota, FL, USA), as detailed previously [24]. Oocytes
were maintained at 19°C in sterile oocyte Ringer’s solution
[ O R i :9 0m MN a C l ,1m MK C l ,1m MC a C l 2,1m MM g C l 2
and 10 mM hydroxyethylpiperazine ethanesulfonic acid
(HEPES), pH 7.4] supplemented with 50 μg/ml of gentamicin.
Heterologous expression in HEK293 cells
cDNAs encoding P2X subunits in pcDNA3.1 vector
(Invitrogen, Karlsruhe, Germany) or the splicing factor
SF3B1 in EGFP-C1 vector were transiently transfected into
HEK293 cells using Lipofectamine LTX (Invitrogen,
Karlsruhe, Germany). Cells were cultured at 37°C in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitro-
gen) supplemented with 10% (v/v) fetal calf serum (FCS)
(PAA Laboratories, Linz, Austria), 100 U/ml of penicillin G
and 100 μg/ml of streptomycin.
Metabolic [
35S]methionine labelling of oocytes
For metabolic [
35S]methionine labelling of oocyte-expressed
recombinant proteins, cRNA-injected oocytes and non-
injected controls were incubated overnight with L-[
35S]
methionine (>40 TBq/mmol; PerkinElmer, Boston, MA,
USA) at about 100 MBq/ml (0.4 MBq per oocyte) in ORi at
19°C, and then chased for 24 h.
Surface fluorescence labelling of oocytes
Selective fluorescence labelling of plasma membrane-
bound P2X receptors was achieved by using the amino-
reactive fluorescent Cy5 dye (GE Healthcare, Freiburg,
Germany), which is membrane impermeant due to its two
sulfonic acidgroups.TwodaysaftercRNAinjection, oocytes
were washed with oocyte-PBS pH 8.5 (20 mM Na
phosphate, 110 mM NaCl, 1 mM MgCl2), and then incu-
bated for 30 min at ambient temperature with Cy5 dye,
which was diluted 200-fold to a final concentration of
50 μg/ml from a dimethyl sulfoxide (DMSO) stock solution.
The reaction was terminated by washing the cells with
oocyte-PBS, followed by membrane protein extraction with
dodecylmaltoside and receptor purification (see below).
Isolation of recombinant P2X receptors from X. laevis
oocytes or HEK293 cells
His-tagged receptors were purified by Ni
2+ nitrilotriacetic
acid (NTA) agarose (Qiagen, Hilden, Germany) affinity
chromatography from non-ionic detergent extracts of
oocytes or HEK293 cells in the presence of iodoacetamide
essentially as described [3, 8, 25]. Slight modifications
were that buffers were supplemented with ethylenediamine-
tetraacetate (EDTA)-free Halt™ protease inhibitor cocktail
(Pierce, Rockford, IL, USA), 50 mM NaF and 50 mM
Na4P2O7 for phosphatase inhibition, and that digitonin was
replaced by 0.2% and 0.05% dodecylmaltoside for mem-
brane protein extraction and repetitive washing of resin-
bound proteins, respectively. Proteins were released from the
washed Ni
2+ NTA agarose beads with non-denaturing
elution buffer consisting of 250 mM imidazole/HCl
(pH 7.4) and 0.02% dodecylmaltoside, and then kept at
0°C until analysed on the day of purification.
In addition, immunoprecipitation assays were performed
using either cRNA-injected Xenopus oocytes or transiently
transfected HEK293 cells. Cells were lysed in ice-cold
immunoprecipitation lysis buffer containing 150 mM NaCl,
25 mM Tris/HCl pH 7.4, 20 mM NaF, 20 mM Na4P2O7,
10 μl/ml Halt™ protease inhibitor cocktail without EDTA
(Pierce, Rockford, IL, USA), 1% sodium dodecyl sulfate
(SDS) (w/v) and 50 mM iodoacetamide. For efficient
solubilization, lysates were incubated for 30 min on ice
with occasional vortexing, and then cleared by centrifuga-
tion for 15 min at 16,100 g and 4°C. The cleared SDS
extract was diluted 1:1 with immunoprecipitation binding
buffer [150 mM NaCl, 20 mM Tris/HCl pH 7.4, 0.4 mM
phenylmethylsulfonyl fluoride (PMSF), 0.5% Triton X-
100 v/v and 25 mM iodoacetamide], supplemented 1:1,000
with the desired peptide-specific P2X2 or P2X3 antibodies
or a polyclonal goat anti-EGFP antibody (Rockland,
Gilbertsville, PA, USA) and incubated for 2 h on ice.
Immunocomplexes were bound to the protein A Sepharose
by overnight head-over-head rotation at 8°C, then washed 5
times with immunoprecipitation binding buffer containing
0.1% Triton X-100 and finally eluted by incubating the
beads for 15 min at 56°C in reducing sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
sample buffer.
In vitro PKC phosphorylation assay
In vitro phosphorylation assays were performed by using
P2X receptors as substrates, purified as detailed above. In
addition, a selective peptide PKC substrate (RRGRTGRG
RRGIYR, Calbiochem-Merck, Darmstadt, Germany, final
concentration 150 μM) corresponding to the amino acid
sequence 1487-1500 of the hepatitis C virus polyprotein
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peptide were incubated for 30 min at 30°C with 0.02 unit
(0.02 μg) of purified catalytic PKC subunit from rat brain
and 50 μM[ γ-
32P]ATP (10 mCi/ml, Amersham Bioscien-
ces GE Healthcare, Freiburg, Germany) in phosphorylation
buffer containing 6 mM CaCl2, 10 mM MgCl2,2 0m M
Tris/HCl pH 7.5, 1 mM EDTA, 1 mM mercaptoethanol,
0.05% Triton X-100 (v/v) and 0.1 mg/ml BSA. The reaction
was terminated by boiling in reducing SDS-PAGE sample
buffer for 30 s. Proteins were resolved by reducing SDS-
PAGE and visualized by immunoblotting or phosphorimag-
ing as detailed below.
In vivo phosphorylation assay
Transiently transfected HEK293 cells were metabolically
labelled by a 3-h incubation with 500 μCi/ml of [
32P]
orthophosphate (Amersham Biosciences GE Healthcare,
Freiburg, Germany) in phosphate-free oocyte Ringer solu-
tion or in phosphate-free DMEM (Invitrogen, Karlsruhe,
Germany) as appropriate. Cells were treated with or without
100 nM phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich, Taufkirchen, Germany) or 100 nM calyculin A
(Tocris Bioscience, Ellisville, MO, USA) for 10 min at
ambient temperature. Non-incorporated radioactivity was
removed by rinsing the cells twice with tracer-free medium.
Affinity purification or immunoprecipitation was performed
as described above followed by SDS-PAGE and immuno-
blotting or phosphorimaging.
SDS-PAGE
Samples for SDS-PAGE were denatured by incubating in
reducing SDS-PAGE sample buffer for 15 min at 56°C and
then electrophoresed on a Laemmli SDS-PAGE gel (10%
acrylamide) in parallel with [
14C]-labelled molecular mass
markers (Rainbow™, Amersham Biosciences GE Health-
care, Freiburg, Germany). Cy5-labelled proteins were
visualized by scanning the wet SDS-PAGE gel with a
fluorescence scanner (Typhoon, GE Healthcare, Freiburg,
Germany). For visualization of radiolabelled or non-
labelled proteins, SDS-PAGE gels were either fixed, dried
and exposed to a PhosphorImager screen, and scanned
using a Storm 820 PhosphorImager (Amersham Bioscien-
ces GE Healthcare, Freiburg, Germany) or/and blotted to
polyvinylidene fluoride (PVDF) membranes.
Immunoblotting
Proteins separated by SDS-PAGE were electroblotted onto
PVDF membranes. Membranes were blocked for 1 h with
5% non-fat milk in PBS (or, alternatively, with 5% BSA if
the phosphothreonine monoclonal antibody was used for
immunoblotting), washed 3×5 min with PBST (0.1%
Tween 20 in PBS) and incubated for 2 h at 4°C in PBS
containing the appropriate primary antibody. Phosphorylat-
ed proteins were detected by immunoblotting with a
phosphothreonine monoclonal antibody (Cell Signaling
Technology, Beverly, MA, USA). Alternatively, the pep-
tide-specific antibodies to P2X2 and P2X3 subunits were
used to verify receptor expression levels. Following
washing in PBST, an appropriate horseradish peroxidase-
conjugated secondary antibody (goat anti-mouse or goat
anti-rabbit, Pierce, Rockford, IL, USA) was applied for 1 h
in PBS supplemented with 1% non-fat milk. After another
3×5 min washes with PBST, immunoreactive bands were
visualized by chemiluminescence imaging using a Fujifilm
LAS-3000 system (Tokyo, Japan) and the AIDA Image
Analyser Software Version 4.08 (Raytest, Straubenhardt,
Germany).
Two-electrode voltage clamp current recordings
and electrical capacitance measurements
Two-microelectrode voltage clamp measurements of X.
laevis oocytes were performed 2 days after cRNA injection
using a Turbo TEC-05 amplifier (npi electronics, Tamm,
Germany) interfaced by an INT-20X AD/DA converter (npi
electronics, Tamm, Germany) to a personal computer
running the CellWorks Lite 5.1 software (npi electronics,
Tamm, Germany), as detailed previously [27–29]. Current
traces were elicited by 100 μM ATP at 1- to 5-min intervals
(Sigma–Aldrich, Taufkirchen, Germany) at a holding
potential of −60 mV in nominally Ca
2+-free bath medium
(designated Mg-ORi) to avoid activation of endogenous
Ca
2+-activated Cl
− channels. ATP was prepared in Mg−ORi
at its final concentration and applied by gravity-fed per-
fusion at a flow rate of 10 ml/min to an oocyte held by the
two microelectrodes in the bath chamber (volume ∼10 μl).
Switching between different perfusion solutions was
achieved with electromagnetic valves controlled by the
CellWorks Lite 5.1 software. Electrophysiological record-
ings were analysed using the Origin 6.0 software (Microcal
Software Inc., Northampton, MA, USA). Single exponen-
tials were fitted to the decay phase of the macroscopic
currents with a nonlinear least squares method. The time
constant τ was taken as an estimate of the rate of receptor
desensitization.
To monitor PMA-induced changes in the oocyte surface
area, depolarizing voltage steps of ΔV=10 mV were applied
from the holding potential to elicit a capacitive transient
Icap, the integral of which yields the charge movement Qcap
and thus the membrane capacitance Cm=Qcap/ΔV [30–32].
PMAwas dissolved in DMSO to a stock solution of 10 mM
and stored at −20°C. On the day of the experiment, the stock
380 Purinergic Signalling (2007) 3:377–388solution was pre-diluted to 100 μM in DMSO and then
further diluted with Mg-ORi to the final concentration of
100 nM. Vehicle control experiments with a final concen-
tration of 0.1% DMSO did not reveal any effects on P2X2
receptor-mediated currents measured with X. laevis oocytes
(results not shown). All measurements were made at room
temperature (21–23°C).
Data analysis
Data are shown as means±SEM. The paired Student’s t-test
(two-tailed) was used to compare current amplitudes with
statistical significance set to p<0.05.
Results
Site-directed modification of a putative N-terminal PKC
site affects the electrophysiological phenotype of P2X2
and P2X3 receptor channels
First, we tested each of the non-mutated and mutant
receptor constructs for expression of an ATP-gated inward
current in cRNA-injected X. laevis oocytes. Application of
100 μM ATP induced typical non-desensitizing currents
through oocyte-expressed P2X2 receptors (Fig. 1c, left
current trace). The P2X2 subunit shares with other P2X
subunit isoforms a conserved consensus site for PKC
phosphorylation (TXR/K, where T is the phosphorylation
Fig. 1 Effect of site-directed modification of a putative PKC motif on
currents mediated by ATP-activated P2X2 and P2X3 receptors. a
Schematic model of the transmembrane topology of the rat P2X3
subunit illustrating the N-terminal position of the
12TTK
14 sequence. b
Alignment of intracellular N-terminal amino acid sequences of the
seven P2X subunit isoforms reveals a highly conserved consensus
motif, TXR/K. c Typical current traces elicited by applying 10-s
pulses of 100 μM ATP to oocytes expressing the indicated wild-type
or mutant P2X2 receptors. d Typical current traces elicited by applying
10-s pulses of 100 μM ATP to oocytes expressing the indicated wild-
type or mutant P2X3 receptors. Gray areas indicate the duration of
ATP application. e All the P2X2 and P2X3 receptors and receptor
mutants were expressed efficiently at the cell surface. Intact, healthy
oocytes expressing the indicated proteins for 2 days were surface-
labelled with the membrane impermeant reactive Cy5 dye and then
extracted with dodecylmaltoside. Recombinant proteins were isolated
by Ni
2+ chelate chromatography and resolved by reducing SDS-
PAGE. Shown is a fluorescence scan of an SDS-PAGE gel
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of the conserved N-terminal PKC site by mutating the
phosphor-acceptor
18T to A resulted in a rapidly desensitiz-
ing channel (Fig. 1c, middle current trace). Also, replace-
ment of
20K by T resulted in a desensitizing phenotype
(Fig. 1c, right current trace). Since PKC preferentially
phosphorylates threonine (or serine) residues that are close
to a C-terminal basic residue, replacement of
20K in the P+2
position by a non-basic residue such as T will destroy the
putative PKC site despite preserving the phosphor-acceptor
18T. Virtually identical findings had previously been
reported by Boue-Grabot et al. [19]. The average half-times
of desensitization (τ) of the
18A and
20T P2X2 mutants were
quite similar, with mean τ values (±SEM) of 4.5±0.4 s and
7.3±0.5 s, respectively, of eight oocytes from two females
per value.
ATP applied to oocytes expressing the P2X3 receptor
elicited a rapidly desensitizing inward current (Fig. 1d, left
current trace) as is typical for this P2X receptor subtype.
Incorporation of similar mutations, as in the P2X2 subunit
in the analogous positions of the P2X3 receptor T
12Ao r
K
14T, completely abolished P2X3 receptor function
(Fig. 1d, middle and right current traces). Visualization of
plasma membrane-bound fluorescence-labelled P2X recep-
tors by affinity purification combined with SDS-PAGE and
fluorescence scanning verified that all the receptors were
efficiently exported to the oocyte surface (Fig. 1e).
The PKC activator PMA augments P2X3 receptor-mediated
currents, yet leaves P2X2-mediated currents unchanged
Since the mutagenesis data for the P2X2 and P2X3 receptor
were consistent with the possibility of a regulatory role for
PKC in P2X receptor function, we examined whether the
PKC activator PMA was capable of affecting the electro-
physiological phenotype of P2X2 or P2X3 receptors. In
planning the experiments, we considered that PMA treat-
ment of X. laevis oocytes is known to induce a pronounced
endocytotic reduction of the cell surface area, as evidenced
microscopically and electrophysiologically by the disap-
pearance of virtually all microvilli and a concomitant
decrease of the electrical capacitance of the plasma
membrane, respectively [31, 32]. Associated with oocyte
surface reduction is a proportional internalization of
membrane proteins, such as endogenous Na
+-K
+ pumps,
suggesting that PMA treatment would stimulate internali-
zation of recombinant P2X receptors as well. Re-examina-
tion of the time course of the PMA-induced reduction of the
oocyte surface area showed that the electrical capacitance
did not start to decline significantly before 10 min after
PMA application (Fig. 2a). Accordingly, all current record-
ings were done within a time window of 10 min after PMA
application to prevent any contribution of receptor inter-
nalization to the PMA effect on P2X receptor-dependent
currents.
Figure 2b and c show typical current traces elicited by
ATP from P2X2 or P2X3 receptor-expressing oocytes
before and after a 10-min exposure to PMA. PMA neither
affected the shape nor the amplitude of P2X2 receptor-
mediated current (Fig. 2b). However, PMA produced a
marked increase of the current amplitude mediated by the
P2X3 receptor (Fig. 2c). In one experiment with four
oocytes, a statistically significant increase of the P2X3-
mediated current amplitude by PMA of 155±42% (SEM)
was determined.
P2X2 and P2X3 receptors exist in a non-phosphorylated
state in both X. laevis oocytes and HEK293 cells
To explain the accelerated desensitization upon site-directed
perturbation of the
18TXK
20 motif, it has been suggested
that the wild-type P2X2 receptor is constitutively phos-
phorylated at
18T and that this phosphorylation is respon-
sible for the slow desensitization rate [19]. To address this
issue, we next examined biochemically whether P2X3
Fig. 2 Effect of PMA on ATP-induced currents mediated by
expressed P2X2 and P2X3 receptors in X. laevis oocytes. a The
electrical membrane capacitance was monitored as a measure of the
oocyte surface area during sustained stimulation with PMA. Each bar
represents the mean Cm±SEM calculated from the areas under the
current transients elicited in 10-s intervals by five consecutive 10-mV
depolarizing steps. b, c Representative current traces elicited by 10-s
lasting pulses of 100 μM ATP applied in 10-min intervals to oocytes
expressing the indicated P2X receptors or P2X receptor mutants.
Where denoted by a black bar, oocytes were pre-incubated with
100 nM PMA before ATP was co-applied. PMAwas without effect on
the P2X2 receptor-mediated current (b), but induced a marked increase
of the current amplitude mediated by P2X3 receptors (c). Gray areas
indicate the duration of ATP application
382 Purinergic Signalling (2007) 3:377–388receptors also exist in a constitutively phosphorylated state;
the P2X2 receptor was also analysed to allow for a direct
comparison of the results. Both parent P2X receptors and
mutants were purified by Ni
2+ chelate affinity chromatogra-
phy from dodecylmaltoside extracts of [
35S]methionine-
labelled oocytes, resolved by SDS-PAGE, and blotted onto a
PVDF membrane. However, probing with a phosphothreonine-
specific monoclonal antibody revealed no discernible signal
(Fig. 3a) despite the presence of significant amounts of
[
35S]methionine-labelled P2X2 and P2X3 protein in the
SDS-PAGE gel (Fig. 3b).
To exclude the possibility that the apparent lack of
receptor phosphorylation resulted from an interference
between the N-terminal His tag and the PKC site of P2X3
or P2X2 receptor subunits, which are separated by only 12
or 20 residues, respectively, we performed analogous
experiments with a C-terminally His-tagged P2X2 receptor,
P2X2-His. As apparent from Fig. 3c, neither N-terminally
nor C-terminally His-tagged P2X2 receptor became phos-
phorylated, as evidenced by immunoblotting with a
His-P2X 2
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Fig. 3 Immunoblots show no constitutive phosphorylation of oocyte-
expressed P2X2 or P2X3 receptors. The indicated wild-type or mutant
P2X subunits were purified by Ni
2+ chelate chromatography from
[
35S]methionine-labelled X. laevis oocytes and resolved by denaturing
SDS-PAGE. a Shown is a representative immunoblot probed with a
phosphothreonine-specific monoclonal antibody and a peroxidase-
conjugated secondary antibody. No phosphorylation signal could be
detected at the SDS-PAGE migration position of P2X2 and P2X3
subunits, which are indicated by the adjacent PhosphorImager scan in
panel b. b Direct PhosphorImager visualization of metabolically [
35S]
methionine-labelled parent and mutant P2X subunits resolved by
SDS-PAGE of the same samples as in panel a. c Left panel:
representative immunoblot of P2X2 subunits tagged with either an
N-terminal or C-terminal hexahistidine sequence (designated His-
P2X2 or P2X2-His, respectively) and probed with a phosphothreonine-
specific monoclonal antibody and a peroxidase-conjugated secondary
antibody. No phosphorylation signal could be detected at the SDS-
PAGE migration position of P2X2 subunits, which were visualized by
immunoblotting with the P2X2 subunit polyclonal antibody (middle
panel) or PhosphorImager scanning of incorporated [
35S]methionine
(right panel)
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Fig. 4 Immunoblotting reveals no constitutive phosphorylation of
HEK293 cell-expressed P2X2 and P2X3 receptors. The indicated
proteins were isolated by immunoprecipitation using the peptide-
specific P2X3 subunit polyclonal antibody or an EGFP-specific
polyclonal antibody as appropriate and resolved by reducing SDS-
PAGE. a Shown is an immunoblot probed by phosphothreonine-
specific monoclonal antibody and a peroxidase-conjugated secondary
antibody. Note that phosphorylation of the P2X3 receptor or the
EGFP-tagged P2X2 receptor is not detectable, whereas a positive
control—the EGFP-tagged splicing factor SF3B1 (migration mass
97 kDa [23])—was detected by the antibody. b The same samples as
in panel a were immunoblotted using peptide-specific P2X2 and P2X3
subunit polyclonal antibodies to verify the expression of the trans-
fected genes
Purinergic Signalling (2007) 3:377–388 383phosphor-specific anti-threonine antibody (Fig. 3c). The
presence of P2X2 receptor protein was verified by immu-
noblotting and metabolic labelling with [
35S]methionine
(Fig. 3c, middle and right panel).
Boue-Grabot et al. [19] have demonstrated phosphory-
lation of P2X2 receptors expressed in HEK293 cells. To
address the possibility that P2X receptor phosphorylation is
host cell specific, we analysed HEK293 cells transiently
transfected with P2X2 or P2X3 expression plasmids. P2X
receptor proteins were isolated by immunoprecipitation and
resolved by reducing SDS-PAGE. The efficient expression
of the P2X3 receptor or the C-terminally EGFP-tagged
P2X2 receptor in HEK293 cells was verified by immuno-
blotting with subunit bands migrating at 54 kDa or 83 kDa
(27 kDa contributed to the P2X2 subunit by the EGFP tag),
respectively (Fig. 4b). However, phosphorylated P2X2 or
P2X3 subunits could not be detected by immunoblotting
with a phosphothreonine-specific antibody (Fig. 4a). In
contrast, the PKC-phosphorylated splicing factor SF3B1,
which was expressed in HEK293 cells as a positive control
substrate and immunoprecipitated with an EGFP antibody,
was efficiently phosphorylated under identical conditions,
assuring that the assay was able to detect phosphorylated
proteins (Fig. 4a, lane 1). Taken together, these results
suggest that both P2X2 and P2X3 receptors exist constitu-
tively in a non-phosphorylated state in both X. laevis
oocytes and HEK293 cells.
PMA-activated PKC does not drive the phosphorylation
of P2X2 or P2X3 receptors
A majority of protein kinases are quiescent unless their
activity is stimulated by specific stimuli and effectors. To
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Fig. 5 Lysates of X. laevis oocytes or HEK293 cells contain
endogenous PKC, but do not support PMA-driven phosphorylation
of P2X2 or P2X3 receptors. The indicated wild-type and mutant P2X
receptors were purified by non-denaturing Ni
2+ chelate chromatogra-
phy from X. laevis oocytes, supplemented with [γ-
32P]ATP, 100 nM
PMA and oocyte lysate (a) or HEK293 cell lysate (b), and incubated
for 30 min at ambient temperature. In parallel, a peptide PKC
substrate (final concentration 0.5 μg/μl) was incubated with [γ-
32P]
ATP, PMA and either of the two cell lysates or the purified rat brain
PKC catalytic subunit as indicated. The proteins were resolved by
reducing SDS-PAGE and visualized by phosphorimaging. Note that
the band pattern was similar irrespective of whether protein of mock-
injected oocytes or P2X receptor-expressing oocytes was used as a
substrate, arguing against specific labelling of either P2X receptor.
Arrows indicate migration positions of P2X1,P 2 X 2 and P2X3
subunits. Arrowhead in a, dominant background band that is present
in all oocyte samples. The peptide PKC substrate was similarly labelled
by lysates or purified rat brain PKC, confirming the presence of
endogenous PKC in X. laevis oocytes and HEK293 cells. c The same
samples as in panels a and b were resolved on a separate SDS-PAGE
gel. The indicated P2X subunits were detected by immunoblotting
using the appropriate P2X subunit-specific polyclonal antibodies. A
sample of mock-transfected cells was simultaneously probed with the
P2X2 and P2X3 subunit-specific polyclonal antibodies
384 Purinergic Signalling (2007) 3:377–388drive phosphorylation by active endogenous PKC, we
incubated non-denatured recombinant His-tagged P2X1,
P2X2 and P2X3 receptors isolated by Ni
2+ NTA agarose
affinity chromatography from dodecylmaltoside extracts of
X. laevis oocytes with PMA-stimulated lysates of X. laevis
oocytes (Fig. 5a) or HEK293 cells (Fig. 5b) in the presence
of [γ-
32P]ATP. As a positive control, a specific peptide
PKC substrate RRGRTGRGRRGIYR was incubated with
the lysates. This peptide was equally well phosphorylated
by addition of either cell lysate or a commercial preparation
of the rat brain PKC subunit (Fig. 5a, b). In contrast,
however, no
32P incorporation could be detected in the
SDS-PAGE migration position of the P2X1,P 2 X 3 or P2X2
receptor subunit at 56 kDa, 54 kDa or 66 kDa, respectively.
The presence of purified P2X1, P2X2 and P2X3 receptor
subunit protein in this assay was verified by immunoblot-
ting using P2X1-, P2X2-o rP 2 X 3-specific antibodies
(Fig. 5c). The phosphorylation of the synthetic peptide
clearly demonstrates that both X. laevis oocytes and
HEK293 cells contain sufficient endogenous PKC to drive
at least the phosphorylation of a synthetic peptide substrate.
Discernible phosphorylation of P2X2 and P2X3 receptors
might be obscured by a low level of endogenous PKC.
Therefore, an analogous experiment was performed, in
which the purified P2X2 and P2X3 receptors were incubat-
ed with purified rat brain PKC catalytic subunit rather than
cell lysate in the presence of [γ-
32P]ATP. Again, the
specific peptide PKC substrate was efficiently phosphory-
lated as demonstrated both by direct phosphorimaging
(Fig. 6a) and immunoblotting with the phosphothreonine
monoclonal antibody (Fig. 6b). Phosphorylated P2X2 or
P2X3 subunits could not be detected by either method
(Fig. 6a, b) despite the presence of abundant amounts of the
respective P2X subunits in the assays (Fig. 6c).
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Fig. 6 PKC phosphorylates a specific PKC substrate in vitro, but
does not phosphorylate P2X2 or P2X3 receptors. The immunopreci-
pitated recombinant P2X2 or P2X3 receptor from X. laevis oocytes or a
synthetic peptide (1 or 10 μg) derived from the non-structural protein
3 of hepatitis C virus, which serves as a specific substrate for PKC,
were incubated for 30 min with purified rat brain PKC catalytic
subunit (0.02 μg corresponding to 0.02 U/μl) in the presence of
50 μM[ γ-
32P]ATP (10 mCi/ml), and then subjected to SDS-PAGE
and phosphorimaging. The rat brain PKC catalytic subunit does not
require Ca
2+ and phosphatidylserine for activity [42].
32Pw a s
incorporated into the PKC substrate (left panel) and was also detected
by immunoblotting with an anti-phosphothreonine antibody (middle
panel). However, there was no detectable
32P incorporation at a
migration position of ∼66 kDa or ∼54 kDa of the P2X2 or P2X3
subunit, respectively, the presence of which could be verified by
immunoblotting (right panel)
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Fig. 7 PMA and calyculin A do not induce phosphorylation of P2X3
receptors in intact HEK cells. Mock- and P2X3 receptor-transfected
HEK293 cells were incubated with [
32P]orthophosphate (500 μCi/ml)
for 3 h in phosphate-free DMEM, followed by a 10-min incubation
with 100 nM of each, the PKC activator PMA and/or the phosphatase
inhibitor calyculin A. Triton X-100 extracts were then prepared from
the cells and subjected to immunoprecipitation using the peptide-
specific P2X3 subunit polyclonal antibody, followed by reducing
SDS-PAGE and phosphorimaging. The migration position of the P2X3
subunit is marked by an arrow, indicating the absence of
32P
incorporation into the P2X3 subunit. P2X3 receptor expression was
verified by immunoblotting with the P2X3 subunit polyclonal
antibody (bottom panel)
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of P2X3 receptors in intact HEK cells
In a final set of experiments, we attempted to directly demon-
strate phosphorylation in vivo by using metabolic [
32P]
orthophosphate labelling combined with immunoprecipita-
tion analysis as a read out. Mock-transfected and P2X3
receptor-transfected HEK293 cells were incubated with
[
32P]orthophosphate in phosphate-free DMEM, followed
by incubation with the PKC activator PMA and/or the
phosphoserine/phosphothreonine phosphatase inhibitor caly-
culin A. The PhosphorImager scan revealed an identical
pattern of phosphorylated bands almost irrespective of the
experimental conditions, with no evidence for a significant
32P-labelling of the P2X3 subunit (Fig. 7, top panel). P2X3
receptor expression was verified by immunoblotting (Fig. 7,
bottom panel).
Discussion
Both P2X3 and P2X2+3 receptors are present on sensory
neurons, where they play an important role in nociception.
In addition to mediating transient nociceptive responses,
these receptors contribute critically to the hyperexcitability
that underlies abnormal pain states elicited by nerve
injuries. One mechanism for the increased responsiveness
to ATP is sensitization of P2X3 and P2X2+3 receptors arising
from a significant enhancement in the trafficking of P2X3
subunit-containing receptors and/or an increase in function
of pre-existing receptors [17]. An obvious candidate
mechanism for functional modulation is phosphorylation,
which is believed to occur universally in all ligand-gated
ion channels as reviewed by Levitan [33].
Evidence for a control of P2X receptor channel function by
PKC-mediated phosphorylation
Site-directed elimination of the putative N-terminal PKC
site has already previously been shown to severely affect
the electrophysiological phenotype of several P2X receptor
subtypes, including P2X1, P2X2 and P2X3 receptors from
rat and/or human [16, 19, 20, 34] and P2X5 receptors from
frog [35]. Replacing the putative phospho-acceptor residue
18T or the basic residue in the P+2 position (
20K) by A or a
non-basic residue, respectively, imposed rapidly desensitiz-
ing properties onto the non-desensitizing wt P2X2 receptor
without grossly affecting the current amplitude. In contrast,
when analogous mutations were introduced into the rapidly
desensitizing receptor subtypes P2X1 or P2X3,p e a k
currents declined to low or undetectable levels, respectively
[16 ,20, 34]; the same observation was also made with the
slower desensitizing frog P2X5 receptor [35]. Overall, the
results obtained by site-directed elimination of the N-
terminal TXR/K motif can be plausibly reconciled with the
hypothesis that the rate of P2X receptor channel desensiti-
zation is controlled by a phosphorylation-dephosphorylation
mechanism, with phosphorylation at this site being associ-
ated with a decreased rate of desensitization.
Additional evidence for a possible involvement of PKC-
dependent phosphorylation comes from experiments with
the PKC activator PMA, which was consistently found to
elicit a severalfold increase in currents mediated by the
P2X1 receptor [36] or the P2X3 receptor [16, 18, 21] with-
out changing the rate of desensitization. A PMA-induced
change of the current desensitization was noted for C-
terminally truncated P2X2 receptors, which are known to
exhibit a desensitizing phenotype in contrast to the parent
full-length P2X2 receptors [19, 37]. PMA treatment
converted the rapidly desensitizing phenotype of truncated
P2X2 receptors to slowly desensitizing, but did not affect
the kinetic properties or current amplitudes of the full-
length P2X2 receptors. The same lack of effect of PMA has
been observed with wild-type P2X2 receptors stably
expressed in HEK293 [38]. It has been inferred from these
data that P2X2 receptors are constitutively phosphorylated
and that this phosphorylation is responsible for their non-
desensitizing phenotype. Consistent with this view, immu-
noblot analysis with a phosphothreonine-proline-specific
monoclonal antibody efficiently detected wild-type P2X2
receptors with an intact PKC site, but not P2X2 receptor
mutants with a disrupted PKC site [19]. Constitutive
phosphorylation has been also demonstrated for the P2X1
receptor expressed in HEK293 cells [34]. Further studies
demonstrated that exogenously added uridine triphosphate
(UTP) potentiated the current mediated by endogenous and
expressed P2X3 receptors in response to αβ-meATP as
agonist. Substitution of phospho-acceptor residues of PKC
consensus sites located in the ectodomain of the P2X3
receptor abolished this UTP-induced current potentiation,
suggesting a role of ecto-protein kinase C in P2X3 receptor
regulation [39, 40].
Evidence against a control of P2X receptor channel
function by PKC-mediated phosphorylation
In direct contrast to the results of Boue-Grabot et al. [19],
we were unable to demonstrate a direct phosphorylation of
wild-type P2X2 receptors expressed in X. laevis oocytes and
HEK293 cells. The various experimental approaches for
phosphorylation detection that we applied included immu-
noblot analysis of purified P2X2 receptors. In the experi-
ments shown, we used a phosphothreonine-specific
monoclonal antibody instead of a phosphothreonine-pro-
line-specific antibody, because the TXK motif of the P2X3
receptor contains a threonine in the -X-position instead of
386 Purinergic Signalling (2007) 3:377–388the proline found in the amino acid sequence of the P2X1
and P2X2 subunit (cf. Fig. 1b). However, even when we
used the same phosphothreonine-proline-specific antibody
as Boue-Grabot et al. [19], we could not demonstrate
phosphorylation of P2X2 receptors in our experiments (data
not shown).
Recently, it has been shown that a proline in the P+1
position strongly disfavours substrate recognition by PKC
[41], suggesting that our negative results with P2X2
receptors may not result from technical limitations, but
reflect the inherent inability of P2X2 receptors to serve as
substrates for PKC. Notably, P2X3 receptors, despite
harbouring a T in the P+1 position, could also not be
demonstrated to become phosphorylated by PKC in our
experiments, as well as in a recently published paper [21].
Further evidence against a direct PKC-mediated P2X
receptor phosphorylation comes from co-expression studies
of P2X1 and G protein-coupled receptors. Co-expression of
the metabotropic glutamate receptor mGluR1α with P2X1
receptors produced a 2.5-fold increase of the P2X1
receptor-mediated current that was blocked by the PKC
inhibitor staurosporine and could be mimicked by PMA
treatment of singly expressed P2X1 receptors. Although the
pharmacological data are basically consistent with PKC-
mediated receptor phosphorylation being involved, mutant
P2X1 receptors with a disrupted N-terminal PKC site
(T
18V) still showed PMA-mediated and mGluR1α-mediat-
ed potentiation. Also, PMA treatment did not lead to an
increase in the (rather weak) basal phosphorylation of the
P2X1 receptor [36].
Functional data supporting a role of PKC in P2X receptor
regulation have been detailed above. There are, however,
also functional data that are inconsistent with the view that
the TXR/K motif represents a true PKC site: (1) replacement
of the phospho-acceptor threonine by an acidic residue to
mimic incorporation of a negatively charged phosphate
group by constitutive phosphorylation was unable to restore
the function of P2X1 receptors [34] and P2X3 receptors
[16]; (2) the PMA-induced potentiation of hP2X1 receptor
currents could be blocked by the PKC inhibitor staurospor-
ine, but surprisingly, not by site-directed elimination of the
PKC site [36]; thus it is much more likely that PMA exerts
its effect on the P2X1 receptor (and the P2X3 receptor)
through a yet to be identified accessory protein.
Taken together, there is no doubt that the TXR/K motif
plays an important role in the functioning of P2X receptors,
and that PMA is capable of modulating P2X1- and P2X3-
mediated receptor currents. The underlying mechanism,
however, is unlikely to involve direct PKC-mediated
phosphorylation of P2X receptors. The existence of a
proline in the P+1 position in several P2X subunit isoforms
(P2X1,P 2 X 2,P 2 X 4) might be one causative factor
preventing direct phosphorylation by PKC. Additional
steric constraints may explain why P2X3 receptors also do
not serve as PKC substrates, despite lacking the proline in
P+1. The exact role of the TXR/K motif awaits further
clarification.
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